Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
This S&G is intended to provide a common understanding of the framework in which External Education, led by Medical Affairs, ultimately benefits patients. The intent is to provide guidance and recommendations to Medical Affairs professionals and offer practical tools for planning, executing, and evaluating external education activities and funding determinations.
This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.
Altmetric’s top 10 most interesting publications of 2024
Experts from Wiley discuss a strategy-driven approach to Medical Education, powered by timely, credible information delivered in multiple formats.
This series of the Elevate Podcast illuminates how AI and Generative AI seem to be a part of every webinar, conference, and conversation these days. This podcast will explore three proof-of-concept (POC) use cases from recent work in the field of Medical Information.
Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores how Sumitomo Pharma America (SMPA) leveraged H1’s advanced data capabilities to integrate diverse insights, enhance field medical strategies, and foster cross-functional collaboration across therapeutic areas.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Consequently, Pharma companies are increasingly including real-world studies in their evidence to:
• Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence
• Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies
• Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle
• Discuss barriers and propose solutions to optimal patient engagement in real-world studies
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.